Abstract Number: PB0821
Meeting: ISTH 2021 Congress
Background: Both recombinant human thrombopoietin (rhTPO) and eltrombopag are recommended second-line drugs for the treatment of immune thrombocytopenia (ITP).
Aims: This double-blind, double-dummy controlled study aims to explore which drugs are more suitable for the rapid increase of platelets in Chinese ITP patients.
Methods: 96 patients were 1:1 randomly assigned to receive eltrombopag 25 mg/day or rhTPO 300 U/kg for 2 weeks.
The primary endpoint was the proportion of patients achieving platelet counts ≥50×109/L at day 15. Secondary endpoints included the platelet response, time to response, and adverse events during treatment. The primary endpoint was achieved in 75% (36/48) of patients in the rhTPO group and 43.75% (21/48) in the eltrombopag group, p=0.003. Complete response was achieved in 64.58% of patients in the rhTPO group vs 25.00% of patients in the eltrombopag group. The proportion of patients whose platelets increased twice more than baseline or reached ≥50×109/L at least once was higher in the rhTPO group on days 9, 12, and 15. The time to increase the platelets twice more than the baseline (p=0.048) or achieve the platelets ≥50×109/L (p=0.048) was shorter in the rhTPO group. However, after treatment, the platelets dropped to the baseline within 1 week in the rhTPO group, while platelets dropped slowly in the eltrombopag group. Adverse events have no significant difference between the two groups.
Conclusions: Compared to the rhTPO, the dose of 25mg eltrombopag may be insufficient to rapidly increase platelets to a safe level in Chinese ITP patients. This study is registered with ClinicalTrials.gov, number NCT03771378.
To cite this abstract in AMA style:Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang R, Qin J, Lv T, Qin F, Cai H, Yin P, Qin T, Hu Y. A Multicenter Double-blind, Double-dummy, Randomized Study of rhTPO vs Eltrombopag in the Treatment of Chinese Immune Thrombocytopenia [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-multicenter-double-blind-double-dummy-randomized-study-of-rhtpo-vs-eltrombopag-in-the-treatment-of-chinese-immune-thrombocytopenia/. Accessed December 6, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-multicenter-double-blind-double-dummy-randomized-study-of-rhtpo-vs-eltrombopag-in-the-treatment-of-chinese-immune-thrombocytopenia/